{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:15:46Z","timestamp":1793344546675,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:p>Oligometastatic non-small-cell lung cancer (NSCLC) is potentially curable. Oligo-recurrence occurs with oligometastatic disease characterized by well-controlled primary lesion. The purpose of the present study was to explore the value of definitive local therapy (DLT) for extracranial single-organ oligorecurrent NSCLC. A total of 81 patients with NSCLC who had extracranial single-organ oligorecurrence after receiving radical treatment at the Cancer Hospital of the University of Chinese Academy of Sciences from January 2010 to December 2017 were analyzed. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS). The median follow-up time of the 81 patients was 65.8 months. A total of 39 patients received DLT. A large proportion of patients who did not accept DLTs received specific tyrosine kinase inhibitors (TKIs). The results of multivariate analysis showed that DLT and specific TKI therapy were favorable prognostic factors significantly related to PFS. Further analysis showed that for patients without specific TKI therapy, DLT significantly improved PFS and the 5-year PFS rate. The 5-year OS rate also improved, but the improvement was not significant. For extracranial single-organ oligorecurrent NSCLC, PFS was significantly superior in patients receiving DLT. Among them, for the subgroup of patients who did not receive specific TKI therapy, DLT is expected to improve long-term prognostic outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000031918","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T22:03:33Z","timestamp":1669845813000},"page":"e31918","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Definitive local therapy for extracranial single-organ oligorecurrent non-small-cell lung cancer: A single institutional retrospective study"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-9276","authenticated-orcid":false,"given":"Jia-Nan","family":"Jin","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Ward, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)\/Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yue","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)\/Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China"},{"name":"Dr.Neher\u2019s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau (S.A.R.), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Qiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Bo","family":"Song","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)\/Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases.","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","article-title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.","volume":"82","author":"Ashworth","year":"2013","journal-title":"Lung Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and oligo-recurrence: the new era of cancer therapy.","volume":"40","author":"Niibe","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"261096","DOI":"10.1155\/2012\/261096","article-title":"Novel insights of oligometastases and oligo-recurrence and review of the literature.","volume":"2012","author":"Niibe","year":"2012","journal-title":"Pulm Med"},{"key":"R6-20250504","first-page":"524","article-title":"Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model.","volume":"244","author":"Adam","year":"2006","journal-title":"Ann Surg"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"290S290S290s","DOI":"10.1378\/chest.07-1382","article-title":"Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).","volume":"132","author":"Shen","year":"2007","journal-title":"Chest"},{"key":"R8-20250504","first-page":"5172","article-title":"Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements.","volume":"46","author":"Price","year":"1986","journal-title":"Cancer Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.ijrobp.2012.02.054","article-title":"Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.","volume":"84","author":"Lopez Guerra","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ejcts\/ezr042","article-title":"Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?","volume":"41","author":"Mordant","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2018.11.017","article-title":"Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta-analysis.","volume":"126","author":"Petrelli","year":"2018","journal-title":"Lung Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.lungcan.2013.08.006","article-title":"Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer.","volume":"82","author":"Yano","year":"2013","journal-title":"Lung Cancer"},{"key":"R13-20250504","first-page":"156","article-title":"Systemic treatment options for brain metastases from non-small-cell lung cancer.","volume":"32","author":"Bulbul","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.ejca.2015.08.008","article-title":"Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based study.","volume":"51","author":"Hendriks","year":"2015","journal-title":"Eur J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial.","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jtcvs.2005.11.028","article-title":"Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?","volume":"131","author":"Hishida","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jso.21750","article-title":"Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.","volume":"102","author":"Yano","year":"2010","journal-title":"J Surg Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ejcts\/ezv249","article-title":"Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival.","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/COC.0000000000000656","article-title":"Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer.","volume":"43","author":"Matsuguma","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2020.38.15_suppl.9508","article-title":"First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"983","DOI":"10.5306\/wjco.v11.i12.983","article-title":"Stereotactic body radiation therapy: a good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.","volume":"11","author":"Mielgo-Rubio","year":"2020","journal-title":"World J Clin Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/JTO.0000000000000686","article-title":"Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer.","volume":"10","author":"Daly","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:04:19Z","timestamp":1746335059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":26,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031918","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}